OmniComm Systems® Announces Reseller Agreement with Tri-I Biotech Shanghai Inc.
Fort Lauderdale, FL, July 10, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQX: OMCM), a global leading provider of clinical data management technology and services, today announced that it has signed a reselling partnership agreement with Tri-I Biotech Shanghai Inc., a market leading China based consultancy providing high performance informatics solutions to over 1,000 medical and clinical research organizations across China, Hong Kong, Macau and Taiwan.
“We were looking for a partner who has a clinical trial system that manages clinical data and automates the data capture and laboratory processes in phase I units,” said Mr. Michael Lee, General Manager at Tri-I Biotech Shanghai Inc. “It is essential that such a system supports both English and Chinese languages and meets the China market requirements. With OmniComm’s TrialOne system, we are confident to sell this first class leading product in China to meet our customers’ demand to improve phase I study management by ensuring the data quality and process efficiency. This partnership will strengthen our position as a market leading solutions provider for Phase I units in China.”
Tri-I works with medical research organizations including the top 50 clinical trial centers in China exclusively on their informatics and clinical data management projects, providing pre-purchase consulting and implementation services. Tri-I also has significant expertise and clients in early phase clinical research, the target market for OmniComm’s TrialOne eSource and clinic automation solution.
TrialOne® is a comprehensive set of modules that drive efficiencies, reduces timelines and costs through faster and more directed volunteer recruitment, easy to build schedule based workflows, real-time bedside data collection, direct data capture from devices, sample processing automation and modern data processing. The browser-based, tablet compatible system provides an advanced platform for automating your clinic operations, complies with FDA 21 CFR part 11, and supports data standards such as CDISC for faster and easier exporting and reporting of data.
“The partnership with Tri-I allows us to bring our market leading Phase I unit automation solution TrialOne to clinical pharmacology centers and Phase I units across China, with implementation services and after sales support in the local language,” says Wolf Ondracek, Senior Vice President Academic and Asian Markets at OmniComm. “Tri-I is experienced in implementing Phase I unit automation solutions and related software systems, and has entry into many of the top tier Phase I units in China. We are absolutely thrilled about this strategic partnership. It is an important step in our further advancement into the Chinese market.”
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
